Bufexamac is a drug used as an
anti-inflammatory agent on the skin, as well as
rectally. Common brand names include Paraderm and Parfenac. It was withdrawn in Europe and Australia[1] because of allergic reactions.
Bufexamac can cause severe
contact dermatitis which is often hard to distinguish from the initial condition.[5] As a consequence, the
European Medicines Agency recommended to withdraw the marketing approval in April 2010.[6]
^Dinnendahl V, Fricke U, eds. (2010). Arzneistoff-Profile (in German). Vol. 2 (23 ed.). Eschborn, Germany: Govi Pharmazeutischer Verlag.
ISBN978-3-7741-9846-3.
^Gloor M, Thoma K, Fluhr J (2000). Dermatologische Externatherapie: Unter besonderer Berücksichtigung der Magistralrezeptur (in German). Springer. p. 349.
ISBN978-3-540-67174-9.
^Bantscheff M, Hopf C, Savitski MM, Dittmann A, Grandi P, Michon AM, et al. (March 2011). "Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes". Nature Biotechnology. 29 (3): 255–265.
doi:
10.1038/nbt.1759.
PMID21258344.
S2CID205275159.